Meta-Analysis of the Placebo Response in Chronic and Episodic Migraine: Insights from Migraine Preventive Drug Trials.

ABSTRACT: Randomized, well-controlled trials are the gold-standard for evaluating novel therapies, but they often fail to fully account for the placebo response, particularly in pain-related conditions such as migraine, where subjective improvement is common in placebo groups. This placebo response is influenced by individual-level factors, such as prior treatment experience, expectations of treatment benefit, and demographic characteristics such as age, race, sex, and clinical trial location. As clinical trials grow increasingly global and diverse, ensuring balanced demographic distribution across treatment arms is essential to accurately assess efficacy. We conducted a meta-analysis of placebo arm data from 14 pivotal Phase 2 and 3 trials that supported approval of six drugs for the preventive tre

SUBMITTER: Nookala AR 

PROVIDER: S-EPMC12906868 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature